What Are ASO Therapies for Myotonic Dystrophy?

Antisense oligonucleotides (ASOs) and similar RNA-targeting drugs are a new class of investigational treatments for myotonic dystrophy type 1 (DM1). You can think of them as “molecular erasers” designed to seek out and destroy the toxic RNA that causes the disease’s symptoms ^[1][2].

To understand how they work, it helps to know what causes DM1. In people with DM1, a mutated gene produces toxic clumps of RNA. These toxic clumps trap essential proteins (called MBNL proteins) that your muscles and organs need to function properly ^[3][4]. ASOs are custom-made genetic sequences that bind directly to this toxic RNA, tagging it so the body’s natural cleanup systems can break it down ^[5][2]. By clearing out the toxic RNA, the trapped MBNL proteins are released to go back to their normal jobs, potentially reversing many of the disease’s effects in the muscles ^[3][4].

Are ASOs a Cure?

While ASO therapies represent a highly promising disease-modifying approach, they are not an approved cure ^[2].

These therapies do not fix the underlying genetic mutation in your DNA ^[6][2]. Because your body will continually produce the toxic RNA, these drugs cannot be given as a one-time treatment ^[5][4]. Instead, they will likely need to be administered regularly—such as through ongoing intravenous (IV) infusions—over a patient’s lifetime to keep the toxic RNA levels low and maintain their benefits ^[7][8]. True permanent cures would likely require gene-editing technologies (like CRISPR) to fix the DNA itself, which is still in much earlier stages of research ^[2][6].

DYNE-101 and AOC 1001: Where Are We Now?

Historically, the biggest challenge with ASOs was getting enough of the drug into skeletal and heart muscle cells, because muscles are dense and highly protective tissues that naturally keep large molecules out ^[9][7]. Two leading drugs in clinical trials—DYNE-101 and AOC 1001—solve this by using innovative “delivery vehicles” (specifically, antibodies) attached to the RNA-targeting drug to ferry it directly into muscle tissues ^[10][11].

Because these delivery vehicles are highly targeted to muscle, it is important to note that they are designed to treat muscle weakness, myotonia, and cardiac issues, but they may not address other DM1 symptoms that originate elsewhere, such as brain fog or gastrointestinal issues.

Both drugs have received “Breakthrough Therapy” designation from the FDA, a status meant to speed up the development and review of drugs for serious conditions ^[12].

• DYNE-101 (Dyne Therapeutics): This drug uses an ASO attached to an antibody to reach muscle cells ^[10]. It is currently being evaluated in a Phase 1/2 clinical trial called the ACHIEVE study, which is testing its safety and early effectiveness ^[13][12].
• AOC 1001 / del-desiran (Avidity Biosciences): This drug uses a slightly different type of RNA targeted therapy (called siRNA) attached to a similar delivery vehicle ^[11][14]. In its Phase 1/2 trial (the MARINA study), the drug successfully reduced toxic RNA levels and showed improvements in muscle biology ^[11]. Based on these positive results, it has advanced to a larger Phase 3 trial called the HARBOR study ^[11][14].

Important Considerations for Clinical Trials

While the progress is exciting, both drugs are still experimental and carry unknown risks. For example, while the MARINA trial showed AOC 1001 was generally well-tolerated, researchers did observe a few serious adverse events at higher doses, which underscores why rigorous safety monitoring is an absolute necessity ^[11].

Clinical trials take time—Phase 3 trials like HARBOR typically take several years to fully complete, analyze, and present data before a drug might be submitted for FDA approval. If you are interested in tracking these trials or seeing if you might be eligible to participate, you can search for the ACHIEVE or HARBOR studies on ClinicalTrials.gov or speak with your neuromuscular specialist.